Pembrolizumab was clinically approved in 2016 as a first-line treatment for metastatic NSCLC in patients with a total proportion score ≥ 50% and without EGFR or ALK mutations after the KEYNOTE 024 and 042 clinical trials [15,16]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.